The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three prior lines of systemic treatment, at least one of which had to
read moreThe company is lowering the annual list price of Tryngolza from $595,000 to $40,000 ahead of an anticipated expansion into the much larger market of severe hypertriglyceridemia. More: Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion
read moreThe FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string of high-profile rejections for rare disease candidates. More: FDA approves Denali's Hunter syndrome drug, handing rare disease community a win Source: fierce
read moreNovartis is facing a class-action lawsuit alleging it shared, without patients’ consent, sensitive health information it collected from visitors to its consumer-facing branded drug websites. More: Novartis sued by breast cancer patient over branded drug websites’ data-sharing practices Source: fierce
read more
Axplora has announced plans to build a 4,500sqm R&D and laboratory hub at its Farmabios site in Gropello Cairoli in Italy More: Axplora announces expansion as newest part of m API investment programme Source: News
read moreUCB will build a new manufacturing facility near its U.S. headquarters in Atlanta, Georgia. It will become the first major manufacturing facility in the U.S. for the rapidly growing Belgium-based company and will produce biologics. The company did not reveal how
read more© 1994 - 2026 B.M. Pharmaceuticals